Paper Details

  1. Home
  2. Paper Details

A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium.

Author: GoldsteinS R, ParsonsA K, RajagopalanS K, ScheeleW H, WalshB W, WilkieJ L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Raloxifene, at 60 or 150 mg/day for 1 year, did not stimulate the postmenopausal endometrium. End-point endometrial thickness, morphology, and uterine volume in the raloxifene groups were similar to those observed at baseline and in the placebo group.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine the effects of a selective estrogen receptor modulator, raloxifene, on postmenopausal endometrium. METHODS: Healthy postmenopausal women (n = 415) were randomly assigned to one of the following four groups: 60 or 150 mg/day raloxifene hydrochloride, 0.625 mg/day conjugated e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0029-7844(99)00502-5

データ提供：米国国立医学図書館（NLM）

Raloxifene: A Selective Estrogen Receptor Modulator's Impact on Postmenopausal Endometrium

This study delves into the [endocrine system], particularly the role of [estrogen] in the [postmenopausal] state. The research focuses on [raloxifene], a medication that acts as a [selective estrogen receptor modulator]. It examines the effects of raloxifene on the [endometrium], the lining of the uterus. The researchers compared raloxifene's effects to those of [estrogen] and [placebo] in a long-term study, providing valuable information for understanding the impact of this medication on women's health.

Raloxifene, a Gentle Touch on the Postmenopausal Endometrium

The results show that raloxifene, even at higher doses, did not stimulate the [endometrium] in [postmenopausal women]. This is a significant finding as it suggests that raloxifene may be a safer alternative to [estrogen] in managing [postmenopausal symptoms], particularly those related to the [endometrium].

Navigating the Desert of Menopause: Finding a Safe Oasis

These findings are reassuring for women experiencing [menopause] and seeking alternative treatment options to [estrogen]. Raloxifene appears to be a gentler alternative, minimizing the potential risks associated with [estrogen] therapy. It's like finding a refreshing oasis in the midst of a vast, challenging desert - a safe haven for women navigating the transition of menopause.

Dr.Camel's Conclusion

This study provides valuable information on the safety and efficacy of raloxifene for postmenopausal women. It demonstrates that raloxifene does not stimulate the endometrium, offering a potentially safer alternative to estrogen therapy. As a wise camel navigating the vast desert, it is crucial to find safe havens and avoid the dangers of the unknown. Raloxifene may be that oasis for women navigating the transition of menopause.

Date :
  1. Date Completed 2000-02-07
  2. Date Revised 2019-08-18
Further Info :

Pubmed ID

10636510

DOI: Digital Object Identifier

10.1016/s0029-7844(99)00502-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.